Table 6.

Factors that may improve patients’ selection in clinical trials

Early development of a new drug (proof of concept), phase I, phase IIa clinical trial	No age limitation but use of biomarkers to enrich the population (Probable AD dementia with evidence of the AD pathophysiological process [22])
	Pure disease
	Short duration
Large clinical trial: phase IIb or phase III clinical trial	No age limitation
	Symptomatic treatment of AD (all ChEI or memantine) authorized with stable dose
	Cerebrovascular lesions scale for MRI interpretation
	Restricted prohibited medication
	Restricted prohibited associated disorder